Displaying 1 - 6 of 6 tests
CMV

In situ hybridization for detection of cytomegalovirus (CMV) RNA.

In Situ Hybridization (ISH)
EBER

This probe set labels all latent EBV-infected cells, including EBV-positive lymphoblastoid cell lines and EBV infected B-cell immunoblasts in infectious mononucleosis. It also reacts with EBV-associated undifferentiated nasopharyngeal carcinomas and with Reed-Sternberg cells in almost all EBV-associated Hodgkin lymphoma cases. Global interpretation is available on head and neck specimens only; tech-only testing is available for all samples.

In Situ Hybridization (ISH)
HER2 Dual ISHThe FDA approved Ventana Medical Systems’ (Ventana) INFORM HER2 Dual ISH DNA Probe set is intended to determine HER2 gene status by enumeration of the ratio of theHER2 gene to Chromosome 17 in formalin-fixed, paraffin-embedded human breast cancer tissue specimens. The INFORM HER2 Dual ISH DNA Probe set is indicated as an aid in the assessment of patients for whom Herceptin (trastuzumab) treatment is being considered. In Situ Hybridization (ISH)
HPV RNA ISH

In situ hybridization on FFPE tissues for qualitative detection of E6/E7 mRNA in up to 28 HPV subtypes with the complete panel: low risk (10 subtypes: 6, 11, 40, 43, 44, 54, 69, 70, 71, 74) plus high risk (18 subtypes: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82). Testing with the complete panel is recommended, but orders for partial panels are accepted. Orderable components are (1) 16/18 High Risk; (2) High Risk Cocktail with all of the previously-named high risk subtypes; and (3) Low Risk Cocktail with all previously-named low risk subtypes. Reports will identify which component or cocktail is positive, but will not identify specific subtypes as positive. Testing is performed only on a global or consult basis at this time. 

In Situ Hybridization (ISH)
KappaEach test contains a set of oligonucleotide probes. The intended target is the kappa light chain immunoglobulin messenger RNA (mRNA) in the cytoplasm of immunoblastic cells, plasma cells and plasmacytoid cells. Assessing the light chain immunoglobulin restriction is important in malignant lymphoma diagnosis. The relationship between monoclonal B-cell proliferation and light chain mRNA restriction aids in the distinction between neoplastic and reactive lymphoid proliferations and the evaluation of multiple myeloma, plasmacytoma, lymphomas with plasmacytoid features, immunoblastic lymphomas and reactive plasma cell proliferations. In Situ Hybridization (ISH)
Lambda

Each test contains a set of oligonucleotide probes. The intended target is the lambda light chain immunoglobulin messenger RNA (mRNA) in the cytoplasm of immunoblastic cells, plasma cells and plasmacytoid cells. Assessing the light chain immunoglobulin restriction is important in malignant lymphoma diagnosis. The relationship between monoclonal B-cell proliferation and light chain mRNA restriction aids in the distinction between neoplastic and reactive lymphoid proliferations and the evaluation of multiple myeloma, plasmacytoma, lymphomas with plasmacytoid features, immunoblastic lymphomas and reactive plasma cell proliferations.

In Situ Hybridization (ISH)